ub.xmlui.mirage2.page-structure.muninLogoub.xmlui.mirage2.page-structure.openResearchArchiveLogo
    • EnglishEnglish
    • norsknorsk
  • Velg spraaknorsk 
    • EnglishEnglish
    • norsknorsk
  • Administrasjon/UB
Vis innførsel 
  •   Hjem
  • Det helsevitenskapelige fakultet
  • Institutt for klinisk medisin
  • Artikler, rapporter og annet (klinisk medisin)
  • Vis innførsel
  •   Hjem
  • Det helsevitenskapelige fakultet
  • Institutt for klinisk medisin
  • Artikler, rapporter og annet (klinisk medisin)
  • Vis innførsel
JavaScript is disabled for your browser. Some features of this site may not work without it.

Effect of everolimus initiation and calcineurin inhibitor elimination on cardiac allograft vasculopathy in de novo heart transplant recipients - Three-Year results of a Scandinavian randomized trial

Permanent lenke
https://hdl.handle.net/10037/14957
DOI
https://doi.org/10.1161/CIRCHEARTFAILURE.117.004050
Thumbnail
Åpne
article.pdf (267.8Kb)
Accepted manuscript version (PDF)
Dato
2018-09-07
Type
Journal article
Tidsskriftartikkel
Peer reviewed

Forfatter
Arora, Satish; Andreassen, Arne K.; Karason, Kristjan; Gustafsson, Finn; Eiskjær, Hans; Bøtker, Hans Erik; Rådegran, Göran; Gude, Einar; Ioanes, Dan; Solbu, Dag; Dellgren, Göran; Ueland, Thor; Aukrust, Pål; Gullestad, Lars
Sammendrag
Background: Cardiac allograft vasculopathy (CAV) limits survival after heart transplantation, and the effect of different immunosuppressive regimens on CAV is not fully understood. The randomized SCHEDULE trial (Scandinavian Heart Transplant Everolimus De Novo Study With Early Calcineurin Inhibitors Avoidance) evaluated whether initiation of the proliferation signal inhibitor everolimus and early cyclosporine elimination can reduce CAV development.

Methods and results: The SCHEDULE trial was a multicenter Scandinavian trial, where 115 de novo heart transplantation recipients were randomized to everolimus with complete cyclosporine withdrawal 7 to 11 weeks after heart transplantation or standard cyclosporinebased immunosuppression. Seventy-six (66%) patients had matched intravascular ultrasound examinations at baseline and 12 and 36 months. Intravascular ultrasound analysis evaluated maximal intimal thickness, percent atheroma volume, and total atheroma volume. Qualitative plaque analysis using virtual histology assessed fibrous, fibrofatty, and calcified tissue as well as necrotic core. Serum inflammatory markers were measured in parallel. The everolimus group (n=37) demonstrated significantly reduced CAV progression as compared with the cyclosporine group (n=39) at 36 months (∆ maximal intimal thickness, 0.09±0.05 versus 0.15±0.16 mm [P=0.03]; ∆ percent atheroma volume, 5.3±2.8% versus 7.6±5.9% [P=0.03]; and ∆ total atheroma volume, 33.9±71.2 versus 54.2±96.0 mm3 [P=0.34], respectively]. At 36 months the number of everolimus patients with rejection graded ≥2R was 15 (41%) as compared with 5 (13%) in the cyclosporine group (P=0.01). Everolimus did not affect CAV morphology or immune marker activity during the follow-up period.

Conclusions: The SCHEDULE trial demonstrates that everolimus initiation and early cyclosporine elimination significantly reduces CAV progression at 12 months, and this beneficial effect is clearly sustained at 36 months.

Beskrivelse
Accepted manuscript version. Published version available at https://doi.org/10.1161/CIRCHEARTFAILURE.117.004050.
Forlag
American Heart Association
Sitering
Arora, S., Andreassen, A.K., Karason, K., Gustafsson, F., Eiskjær, H., Bøtker, H.E. ... Gullestad, L. (2018). Effect of everolimus initiation and calcineurin inhibitor elimination on cardiac allograft vasculopathy in de novo heart transplant recipients - Three-year results of a Scandinavian randomized trial. Circulation: Heart Failure, 11(9), e004050. https://doi.org/10.1161/CIRCHEARTFAILURE.117.004050
Metadata
Vis full innførsel
Samlinger
  • Artikler, rapporter og annet (klinisk medisin) [1974]

Bla

Bla i hele MuninEnheter og samlingerForfatterlisteTittelDatoBla i denne samlingenForfatterlisteTittelDato
Logg inn

Statistikk

Antall visninger
UiT

Munin bygger på DSpace

UiT Norges Arktiske Universitet
Universitetsbiblioteket
uit.no/ub - munin@ub.uit.no

Tilgjengelighetserklæring